Wells Fargo analyst Derek Archila raised the firm’s price target on Annexon (ANNX) to $12 from $11 and keeps an Overweight rating on the shares. The firm believes the risk/reward remains favorable ahead of ANX005’s Phase 3 data in GBS. Additionally, updates for ANX007 at ARVO, Phase 3 GBS data at PNS and read through from Sanofi’s (SNY‘s) riliprubart in CIDP at AAN, all could offer upside for shares, Wells adds.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANNX:
- Annexon Reports Fourth Quarter and Year-End 2023 Financial Results and Key Anticipated Milestones
- Annexon options imply 24.7% move in share price post-earnings
- Annexon participates in a conference call with JPMorgan
- Annexon Biosciences, Inc. (ANNX) Q4 Earnings Cheat Sheet
- Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
